Modulation of Na(+),K(+) pumping and neurotransmitter uptake by beta-amyloid

Q B Gu1, J X Zhao, J Fei

  • 1Shanghai Institute of Biochemistry and Cell Biology, 320 YueYang Road, 200031 Shanghai, China.

Neuroscience
|May 18, 2004
PubMed

Insights

Beta-amyloid (Abeta) inhibits the Na(+),K(+)-ATPase and glutamate transporters (EAAC1) in Alzheimer's disease research. This inhibition of glutamate uptake may contribute to neurotoxicity and disease progression.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Alzheimer's disease pathogenesis involves beta-amyloid (Abeta) peptides.
  • Neurotransmitter transporters, like EAAC1 for glutamate and GAT1 for GABA, are crucial for neuronal function.
  • These transporters rely on the Na(+),K(+)-ATPase for maintaining ion gradients.

Purpose of the Study:

  • To investigate the specific effects of micromolar concentrations of Abeta(1-42) on GABA (GAT1) and glutamate (EAAC1) transporters.
  • To determine the impact of Abeta on the Na(+),K(+)-ATPase activity.
  • To identify the specific Abeta fragments responsible for inhibiting EAAC1.

Main Methods:

  • Xenopus oocyte expression system used to study transporter function.
  • Measurement of ion translocation by Na(+),K(+)-ATPase.
  • Assay of glutamate and GABA uptake rates and transporter-mediated currents.
  • Incubation with various Abeta fragments (Abeta(1-42), Abeta(12-28), Abeta(25-35)) at different concentrations and durations.

Main Results:

  • Brief Abeta(1-42) treatment inhibited Na(+),K(+)-ATPase activity (30-40%) and glutamate uptake (20%), with no effect on GABA uptake.
  • Prolonged incubation with Abeta(1-42) strongly inhibited glutamate uptake and EAAC1 current (>80% after 4h).
  • The Abeta(12-28) fragment showed partial inhibition (50% after 4h at 20 microM), while Abeta(25-35) had minimal effect.
  • Inhibition of EAAC1 was irreversible with prolonged Abeta exposure and mediated by extracellularly applied peptides.

Conclusions:

  • Abeta specifically inhibits the Na(+),K(+)-ATPase and the glutamate transporter EAAC1.
  • The amino acid domain 12-28 of Abeta is critical for EAAC1 inhibition.
  • Inhibition of EAAC1, leading to elevated extracellular glutamate, may contribute to Alzheimer's disease neurotoxicity.

Related Concept Videos

Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...